Sun Pharma Agrees to Largest-Ever Indian Pharma Acquisition with $11.75 Billion Organon Acquisition

Sun Pharma Makes Biggest Acquisition in Indian Pharmaceutical History

Sun Pharma, a leading Indian pharmaceutical company, announced on Monday that it will acquire US-listed Organon & Co. in an all-cash deal valued at an enterprise value of $11.75 billion. This significant transaction marks a decisive step in Sun Pharma's strategy to accelerate its transformation into a large, diversified global drugmaker and secure new growth engines beyond traditional generics.

The acquisition, which values Organon at $14 per share in cash, is aimed at strengthening Sun Pharma's presence across women's health, established brands, and biosimilars, while materially expanding its commercial reach in advanced markets. Organon brings a strong global franchise, with operations across more than 140 countries, leadership in contraceptives and fertility, a sizable portfolio of over 50 established brands, and a rapidly growing biosimilars business.

Read also: Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data

The acquisition is expected to add women's health as a new innovation pillar alongside dermatology, ophthalmology, and onco-dermatology, while also giving Sun Pharma immediate scale in biosimilars, where Organon already ranks among the top global players. In sheer financial terms, the acquisition represents a step-change, with the combined Sun-Organon entity expected to generate $12.4 billion in annual revenue, almost double Sun Pharma's standalone revenue in FY25.

The merged company will draw a greater share of revenues from innovative medicines and branded products, reducing dependence on commoditised generics and creating a more balanced business mix across innovation, established brands, and biosimilars. Sun Pharma has said the transaction will be financed through a mix of $2–2.5 billion of cash on its balance sheet and $9.25–9.75 billion of committed bank financing.

Despite the size of the acquisition, management expects leverage to remain manageable, with net debt-to-EBITDA estimated at around 1.8x on a combined basis, supported by Organon's strong and predictable cash flows. Organon generates over $1 billion in annual free cash flow before financing, which Sun plans to use to deleverage quickly while continuing to invest in research, development, and future business development opportunities.

The integration is expected to deliver potential synergies of over $350 million within two to four years, driven by cost efficiencies, supply-chain optimisation, and the application of Sun Pharma's branded-generics execution playbook to Organon's established brands. Sun also sees significant upside from cross-pollinating products across markets and from using Organon's strong global commercial engine to in-license and scale new therapies.

Read also: US-Iran Tensions Spark Uptick in Oil Prices Amid Global Market Decline

The acquisition builds on Sun Pharma's long history of large, complex transactions, most notably its acquisition of Ranbaxy in 2014, as well as a series of targeted in-licensing deals that strengthened its innovative medicines portfolio. Over the past decade and a half, those moves have underpinned a 14.4% revenue CAGR and a 13% EBITDA CAGR between FY10 and FY25, reinforcing management's confidence in its ability to integrate large businesses and extract value over time.

Once completed, expected in early 2027 subject to shareholder and regulatory approvals, the combined company will have a presence across all major pharmaceutical markets, with 18 countries each generating more than $100 million in revenue and a global commercial workforce of about 24,000 people. The enlarged platform positions Sun Pharma to emerge as a stronger partner for global licensing deals, deepen patient access across therapies and regions, and steadily increase its share of innovative medicines over the medium term.